Cerebrospinal fluid tyrosine and 3,4-dihydroxyphenylacetic acid levels in migraine patients

Cephalalgia

Volumn 16, Issue 1, 1996, Pages 56-61

  Castillo, J ^a   Martinez F ^a   Suarez C ^a   Naveiro, J ^a   Lema, M ^a   Noya, M ^a  

^a HOSPITAL GENERAL DE GALICIA   (Spain)

Author keywords

DOPAC; Dopaminergic system; Migraine with aura; Migraine without aura; Noradrenergic system; Tyrosine

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; TYROSINE;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NORADRENERGIC SYSTEM;

3,4-DIHYDROXYPHENYLACETIC ACID; ADOLESCENT; ADULT; BRAIN; DOPAMINE; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NOREPINEPHRINE; SYNAPTIC TRANSMISSION; TYROSINE;

EID: 0030026952     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1996.1601056.x     Document Type: Article

References (32)

1. Lance JW. The pathophysiology of migraine. In: Dalessio DJ, editor. Wolff's headache and other head pain. New York: Oxford University Press, 1987:58-86
2. Martinez F, Castillo J, Pardo J, Lema M, Noya M. Catecholamine levels in plasma and CSF in migraine. J Neurol Neurosurg Psychiatry 1993;56:1119-21
3. Leira R, Castillo J. Función plaquetaria en la migraña. En: Matías-Guiú J, Vázquez J, Leira R, editors. Isquemia cerebral y migraña. Barcelona: J.R. Prous Editores, 1990:99-116
4. Leira R, Castillo J, Martínez F, Castro A, Lema M, Noya M. Plaquetas y migraña. Correlación entre marcadores bioquímicos de agregación plaquetaria y serotonina. Neurología 1991;6:10-12
5. Leira R, Castillo J, Martínez F, Castro A, Lema M, Noya M. Nucleótidos de la adenina en la migraña. Neurología 1991;6:207-10
6. Martínez F, Castillo J, Leira R, Prieto JM, Lema M, Noya M. Taurire levels in plasma and cerebrospinal fluid in migraine patients. Headache 1993;33:324-7
7. Martínez F, Castillo J, Rodríguez JR, Leira R, Noya M. Neuroexcitatory amino acid levels in plasma and cerebrospinal fluid during migraine attacks. Cephalalgia 1993;13: 89-93
8. Castillo J, Martinez F, Leira R, Prieto JM, Lema M, Noya M. Modificación de los niveles de aminoácidos neuroexcitadores en périodes críticos e intercríticos de migraña. Neurología 1994;9:42-5
9. Bès A, Guell A, Victor G, Bru A, Janzac P, Geraud G. Effects of dopaminergic agonist (piribedil) on CBF in migraine patients. J Cereb Blood Flow Metab 1981;1 Suppl 1:549-50
10. Sicuteri F, Boccuni M, Fanciullacci M, D'Egidio P, Bonciani M. A new nonvascular interpretation of syncopal migraine. Adv Neurol 1982;33:199-208
11. Geraud G, Guell A, Courtado M, Dupmi P, Bès A. Clinical value of a dopaminergic agonist administration in migraine patients. Headache 1983;23:191-2
12. Piccini P, Nuti A, Paoletti AM, Napolitano A, Melis GB, Bonucelli V. Possible involvement of dopaminergic mechanism in the antimigraine action of flunarizine. Cephalalgia 1990;10:3-8
13. Bussone G, Frediani F, Lamperti E, LaMantia L, Vescovi A, Peccarisi C, Boiardi A. Piribedil test in migraine: neuroendocrinological aspects. Headache 1986;26:482-5
14. Mitchelson F. Pharmacological agents affecting emesis. A review (Part II). Drugs 1992;43:443-63
15. Headache Classification Committee of the International Headache Society. Classification and diagnosis criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8 Suppl 7:1-96
16. Diamond S, Medina JL. Double-blind study of propranolol for migraine prophylaxis. Headache 1976;16:24-7
17. Kruk ZL, Pycock CJ. Neurotransmitters and drugs. London: Chapman and Hall, 1991:50
18. Eisenhofer G, Brush JE, Camion RO, Stull R, Kopin IJ, Goldstein DS. Plasma dihydroxyphenylalanine and total body and regional noradrenergic activity in humans. J Clin Endocrinol Metab 1989;68:247-55
19. Roth RH, Murrin LC, Walters JR. Central dopaminergic neurons: effects of alterations in impulse flow on the accumulation of dihydroxyphenylacetic acid. Eur J Pharmacol 1976;36: 163-72
20. Anden NE, Grabowska-Anden M. Formation of deaminated metabolites of dopamine in noradrenaline neurons. Naunyn-Schmiedebergs Arch Pharmacol 1983;324:1-6
21. Palfreyman MG, Huot S, Wagner J. Value of monoamine metabolite determinations in CSF as an index of their concentrations in rat brain following various pharmacological manipulations. J Pharmacol Methods 1982;8:183-96
22. Hutson PH, Curzon C. Dopamine metabolites in rat cisternal cerebrospinal fluid: major contribution from extrastriatal dopamine neurons. J Neurochem 1986;46:186-90
23. Calabresi P, Silvestrini M, Stratta F, Cupini LM, Argiro G, Atzei CP, Bernardi G. 1-Deprenyl test in migraine: neuroendocrinological aspects. Cephalalgia 1993;13:406-9
24. Bonucelli U, Paoletti A, Piccini P, Colzi A, Nuti A, Melis GB, Muratorio A. Neuroendocrine effects of flunarizine in normal and migrainous women. Cephalalgia 1987;7 Suppl 6:256-7
25. Lara Capellan JI, Varela Dacosta C, Gutierrez García JM, Riobo Servan P, Alvarez Cermeño JC. Tuberoinfundibular dopaminergic tonus in common migraine. Headache 1990;30:282-4
26. Eadie MJ, Tyrer JH. The biochemistry of migraine. Lancaster: MTP Press, 1985:65
27. Kovács K, Bors L, Tóthfalusi L, Jelenesi I, Bozsik G, Kerényi L, Komoly S. Cerebrospinal fluid (CSF) investigations in migraine. Cephalalgia 1989;9:53-7
28. Nagel-Leiby S, Welch KMA, D'Andrea G, Grunfeld S, Brown E. Event-related slow potentials and associated catecholaminc function in migraine. Cephalalgia 1990;10:317-29
29. Gallai V, Gaiti A, Sarchielli P, Coata G, Trequattrini A, Paciaroni M. Evidence for an altered dopamine beta-hydroxylase activity in migraine and tension-type headache. Acta Neurol Scand 1992;86:403-6
30. Welch KMA. Migraine. A biobehavioral disorder. Arch Neurol 1987;44:323-7
31. Welch KMA, D'Andrea G, Tepley N, Barkley G, Ramadan NM. The concept of migraine as a state of central neuronal hyperexcitability. Neurol Clin 1990;8:817-28
32. Sicuteri F. Migraine, a central biochemical dysnociception. Headache 1976;16:145-59